Rapid Nutrition Secures Trademark License Agreement for Creapure®, the Gold Standard of Creatine

02 Sep 2025 04:50 CEST

Rapid Nutrition Secures Trademark License Agreement for Creapure®, the Gold Standard of Creatine

Rapid Nutrition introduces a clinically proven, vegan-friendly creatine under the SystemLS™ brand, featuring Creapure®—the world’s most respected creatine—to meet growing consumer demand.

London, United Kingdom – 2 September 2025 – Rapid Nutrition PLC (Euronext Growth: ALRPD), an international HealthTech and wellness company, dedicated to advancing wellness through evidence-based, personalized nutrition solutions, is pleased to announce the signing of a trademark license agreement for the use of Creapure®, widely recognized as the gold standard of creatine monohydrate.

Creapure® is produced in Germany under strict GMP-certified standards and is widely regarded for its purity, safety, and performance. Certified vegan and supported by decades of scientific research, Creapure® aligns perfectly with Rapid Nutrition’s ongoing commitment to delivering best-in-class, clean-label formulations.

“Our brand has always stood for premium, science-backed nutrition,” said Simon St. Ledger, CEO of Rapid Nutrition. “Integrating Creapure® into our SystemLS™ range reflects our mission to deliver world-class products that consumers can trust.”

The new SystemLS™ creatine formula featuring Creapure® will complement the existing SystemLS™ premium product range and support improved strength, energy, and recovery for both men and women seeking effective, everyday health solutions. In addition to its well-established role in athletic performance, creatine is quickly gaining recognition for its cognitive, longevity, and general health benefits, with growing scientific research highlighting its potential to support brain function, healthy aging, and cellular energy metabolism.

With creatine remaining one of the most clinically studied and effective ingredients in nutrition science, this launch further positions SystemLS™ at the forefront of clean-label, results-driven innovation.

The product is expected to launch in late Q4 2025 or early Q1 2026, and will feature the official Creapure® seal and verification code, ensuring authenticity and offering consumers a trusted, clinically backed performance supplement with unparalleled purity and effectiveness.

About Rapid Nutrition

Rapid Nutrition is a global HealthTech company dedicated to advancing wellness through evidence-based, personalized nutrition solutions. Leveraging advanced technologies, AI, and scientific research, the company is committed to optimizing nutrition, improving health outcomes, and fostering sustainable, healthier lifestyles worldwide.

Investor Relations Contact:

ir@rnplc.com

Disclaimer

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).